Anika enters cooperation with Caligan, appoints director, authorizes $20M buyback

Anika Therapeutics, Inc.

Appointed Gary Fischetti as Class III director; Board expands to eight members.
Authorized $20M share repurchase: $5M accelerated, $5M open market, $10M subject to positive cash flow.
Formed Capital Allocation Committee with Fischetti, Henneman, and Thompson.
Caligan agreed to standstill and voting commitments supporting Board's 2023 slate.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gary Fischetti

Class III director

ANIK · Anika Therapeutics, Inc.

Effective: 2023-04-13
Filed: April 13, 2023, 7:59 PM ET

effective April 13, 2023, the Board of the Company increased its size from seven to eight directors and appointed Mr. Fischetti to the Board as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Fischetti was appointed as Class III director at Anika Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

effective April 13, 2023, the Board of the Company increased its size from seven to eight directors and appointed Mr. Fischetti to the Board as a Class III director

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Anika Therapeutics, Inc. entered into Cooperation Agreement with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the 'Investor Group') valued at $20,000,000 (effective 2023-04-13).

Action: entry
Counterparty: Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the 'Investor Group')
Value: $20,000,000
Effective: 2023-04-13

Exact text from the filing

On April 13, 2023, Anika Therapeutics, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the “Investor Group”).

View on SEC.gov

Browse all material agreements →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-100714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.